Bullish Case: CareDx has converted strong operating momentum into a raised FY2026 revenue range of $490–500M, while the MolDx coverage decision and Naveris/NavDx broaden the growth base. CDNA is up 124.6% over 90 days, calls traded 95% more than puts, and Helium’s +3.63% model signal is modestly positive. Moderate ATM IV and concentrated $50–55 price densities leave room for continued re-rating if execution confirms adoption.

Bearish Case: The 124.6% 90-day advance raises disappointment and profit-taking risk despite a flat recent week. Market-implied density is concentrated near $50–55, while illiquid deep puts show extreme quoted IV, signaling poorly measurable but material tail risk. Competitive in-house testing, reimbursement execution, integration, and guidance credibility remain unresolved; a weak update could compress the currently elevated valuation and reverse momentum.

Potential Outcomes:

1. Consolidation $45–55 — 35%: inline guidance and fading momentum; falsified by a >10% move.
2. Re-rate $55–65 — 30%: adoption and NavDx execution validate the raised guide.
3. Pullback $38–45 — 20%: reimbursement, competition, or margin concern.
4. Breakout >$65 — 10%: material partnership or guide raise.
5. Tail <$38 — 5%: regulatory/liquidity shock.

Oracle: bullish confirmation requires sustained trade above $55 with call demand and falling downside IV; failure keeps the consolidation/bear cases active.

September 01, 2026